

FSSA China All Cap Fund

Semi-Annual Report

July 2024 - December 2024



FSSA China All Cap Fund

Contents	Pages
Report of the manager (unaudited)	1 – 2
Investment portfolio (unaudited)	3 – 5
Statement of movements in portfolio holdings (unaudited)	6-7
Details in respect of financial derivative instruments (unaudited)	8
Statement of net assets (unaudited)	9
Statement of comprehensive income (unaudited)	10-11
Statement of changes in net assets attributable to unitholders (unaudited)	12
Cash flow statement (unaudited)	13
General information	14

This semi-annual report shall not constitute an offer to sell or a solicitation of an offer to buy units in the FSSA China All Cap Fund. Subscriptions are to be made only on the basis of the information contained in the relevant Explanatory Memorandum, as supplemented by the latest annual and semi-annual reports.

Performance

	1 July 2024 To 31 Dec 2024	1 July 2023 To 31 Dec 2023
FSSA China All Cap Fund Class I	9.07%	(11.60%)
FSSA China All Cap Fund Class II	9.06%	(11.56%)
FSSA China All Cap Fund Class III	9.34%	(11.34%)
Benchmark: MSCI China Free Index	14.01%	(6.07%)

(Performance calculation is based on the official dealing NAV.)

Performance Review

Key contributors to performance included Meituan, as the company reduced its losses in community group buying (CGB) and conducted share buybacks, a sign of increased focus on shareholder returns and better alignment. Tencent also added to performance as it continued to develop new functions within WeChat (such as Video Accounts and Mini Shops) to slowly improve monetisation and enhance the quality of the franchise.

Shenzhen Mindray fell as the ongoing anti-corruption campaign affected hospitals' demand for medical equipment. We still think it is the highest-quality medical equipment maker in China, and its overseas business delivered robust revenue growth. Shenzhou fell as data in the US and UK suggested soft retail demand, while Nike's cautious outlook hurt sentiment towards apparel makers. In the longer term, we believe Shenzhou could gain market share as brands become more conscious about their supply chain and consolidate in favour of the best quality operators.

Major activity

Significant new purchases included Hundsun Technologies, a leading software provider for the financial industry. The company has a strong track record of growth and is well-positioned to benefit from the long-term development of China's capital markets. Most of its revenue comes from brokers and asset managers, which have scope to increase their IT spending.

The Fund also bought Contemporary Amperex Technology Ltd (CATL), a leading manufacturer of electric vehicle (EV) batteries and energy storage systems. The company is a technology leader in its field and has continued to grow its global market share in recent years, mostly in Europe.

The Fund sold Shenzhen Sunlord and Shanghai Liangxin to consolidate into more attractive opportunities.

Outlook

The Chinese economy is undergoing difficulties, with ongoing deflationary pressure after the property market started correcting three years ago. Overall corporate earnings growth has been under pressure while domestic demand is likely to remain weak. Since September, China's central government has shown a major change in attitude, recognising the need to stimulate consumption and adopt more progressive fiscal and monetary policies. We see the change in policy stance as positive.

As bottom-up investors, we look for companies which we believe can grow earnings in a sluggish growth environment. Perhaps they are gaining market share, monetising existing businesses or simply have stronger pricing power in a more consolidated industry. We have also seen Chinese companies becoming more proactive in returning cash to shareholders, through increased dividends and buybacks. Meanwhile, even though overall demand is weak, there are still certain secular growth trends in China, such as travel. We believe if we stick to our investment philosophy, we can still find pockets of growth and deliver decent returns for our clients in the long run. We also believe well-managed business franchises will emerge stronger after going through a challenging period, as they adapt to the environment and take steps to strengthen their franchises.

	Holdings as at 31.12.2024	Market value US\$	% of net asset value
Listed investments – equities (100.17%)			
Listed on the Stock Exchange of Hong Kong (65.4)	5%)		
ANTA Sports Products Ltd	19,400	194,426	2.71
China Mengniu Dairy Co Ltd	132,000	298,395	4.16
China Merchants Bank Co Ltd - H	51,791	266,691	3.72
China Resources Beer Holdings Co Ltd	114,500	372,186	5.19
China Resources Mixc Lifestyle Services Ltd.	36,200	134,679	1.88
Haier Smart Home Co Ltd - H	57,400	203,207	2.83
H World Group Limited	57,230	191,554	2.67
JD.com Inc - A	18,426	322,600	4.50
Kingdee International Software Group Co Ltd	86,000	94,437	1.32
Meituan	21,350	416,943	5.8
Netease Inc	9,900	176,386	2.40
Shenzhou International Group	33,800	269,775	3.76
Sino Biopharmaceutical Ltd	115,500	47,580	0.60
Sunny Optical Technology Group Co Ltd	21,800	193,221	2.69
Tencent Holdings Ltd	12,400	665,658	9.28
Xinyi Glass Holdings Co Ltd	114,000	115,791	1.62
Yadea Group Holdings Ltd.	162,000	269,863	3.70
Yihai International Holding Ltd	46,000	89,300	1.25
ZTO Express Cayman Inc - A	19,098	371,981	5.19
		4,694,673	65.40

	Holdings as at 31.12.2024	Market value US\$	% of net asset value
Listed investments – equities (100.17%) (continued)			
Listed on the Stock Exchange of New York, U.S.A.			
(5.95 %)			
ACM Research Inc	4,760	71,876	1.00
Atour Lifestyle Hldgs Ltd Sponsored Ads	1,437	38,641	0.53
Kanzhun Ltd	17,865	246,537	3.44
Tencent Music Entertainment Group Sponsored ADR Class A	6,167	69,995	0.98
		427,049	5.95
Listed on the Stock Exchange of Shanghai People's Republic of China (9.60%)			
Changzhou Xingyu Automotive Lighting Systems Co.,			
Ltd Class A	2,100	38,181	0.54
Guangzhou Kingmed Diagnostics Group Co Ltd	15,000	56,249	0.78
Hongfa Technology Co Ltd - A	42,188	182,854	2.55
Hundsun Technologies Inc	10,200	38,888	0.54
Nari Technology Co Ltd - A	9,980	34,284	0.48
Ping An Insurance Group Co	24,200	173,552	2.42
Yifeng Pharmacy Chain Co Ltd	49,984	164,287	2.29
		688,295	9.60
Listed on the Stock Exchange of Shenzhen, People's			
Republic of China (17.27%)			
Bank of Ningbo Co Ltd - A	35,253	116,733	1.63
Beijing New Bldg 'A'CNY1	17,300	71,424	1.00
Centre Testing International Group Co Ltd - A China Resources Boya Bio-Pharmaceutical Group Co	94,800	161,436	2.25
Ltd	8,800	36,296	0.51
Contemporary Amperex Technology Co Ltd	2,198	79,639	1.11
Hangzhou Oxygen Plant Group-A	40,600	120,558	1.68
Midea Group Co Ltd	24,154	247,479	3.45
Shanghai Hanbell Precise Machinery Co Ltd	20,997	52,968	0.74
Shenzhen Inovance Technology Co Ltd	3,400	27,130	0.38
Shenzhen Mindray Bio-Medic - A	7,400	257,032	3.58
Sinoseal Holding Co Ltd	13,200	67,785	0.94
		1,238,480	17.27
Listed on the Stock Exchange of Taiwan (1.89%)			
MediaTek Inc	2,000	86,321	1.20
Silergy Corp	4,000	49,231	0.69
		135,552	1.89

	Market value US\$	% of net asset value
Listed investments – equities (100.17%) (continued)		
Total listed investments – equities	7,184,049	100.17
Other net Liabilities	(12,514)	(0.17)
Net assets as at 31 December 2024	7,171,535	100.00
Total listed investments, at historical cost	7,871,999	

FSSA China All Cap Fund Statement of Movements in Portfolio Holdings (Unaudited) For the period ended 31 December 2024

	Portfolio holdings		Corporate
Listed investments	Additions	Disposals	Actio
Equities			
Listed on the Stock Exchange of Hong Kong			
ANTA Sports Products Ltd	1,400	-	
China Mengniu Dairy Co Ltd	14,000	-	
China Merchants Bank Co Ltd - H	-	8,000	
China Resources Beer Holdings Co Ltd	20,500	-	
China Resources Land Ltd	-	20,137	
China Resources Mixc Lifestyle Services Ltd.	6,400	-	
H World Group Limited	9,700	-	
JD.com Inc - A	-	5,350	
Kingdee International Software Group Co Ltd	-	22,000	
Meituan	1,300	7,900	
Netease Inc	3,700	-	
Shenzhou International Group	15,800	-	
Sino Biopharmaceutical Ltd	-	99,000	
Sunny Optical Technology Group Co Ltd	6,700	2,300	
Tencent Holdings Ltd	-	1,300	
Yadea Group Holdings Ltd.	56,000	-	
ZTO Express Cayman Inc - A	7,000	-	
Listed on the Stock Exchange of New York,			
U.S.A.			
ACM Research Inc	2,136	308	
Atour Lifestyle Hldgs Ltd Sponsored Ads	-	555	
Kanzhun Ltd	5,902	-	
Tencent Music Entertainment Group Sponsored	-)		
ADR Class A	1,977	940	
Listed on the Stock Exchange of Shanghai,			
People's Republic of China			
Autobio Diagnostics Co Ltd - A	-	10,416	
Hongfa Technology Co Ltd - A	-	3,500	
Hundsun Technologies Inc	10,200	-	
Nari Technology Co Ltd - A	- • ,- • •	9,100	
Ping An Insurance Group Co	-	1,700	
Yifeng Pharmacy Chain Co Ltd	17,900	1,700	

FSSA China All Cap Fund Statement of Movements in Portfolio Holdings (Unaudited) (continued) For the period ended 31 December 2024

	Portfolio holdings		Corporate
Listed investments (continued)	Additions	Disposals	Action
<u>Equities (continued)</u>			
Listed on the Stock Exchange of Shenzhen,			
People's Republic of China			
Centre Testing International Group Co Ltd - A	12,800	-	
Chacha Food Co Ltd	-	6,300	
China Resources Boya Bio-Pharmaceutical Group			
Co Ltd	-	12,000	
Contemporary Amperex Technology Co Ltd	2,198	-	
Midea Group Co Ltd	1,590	8,690	
Shanghai Hanbell Precise Machinery Co Ltd	-	8,800	
Shanghai Liangxin Electric Co Ltd	-	88,860	
Shenzhen Mindray Bio-Medic – A	3,100	-	
Shenzhen Sunlord Electronics Co Ltd	-	37,600	
Zhejiang Weixing New Building Materials Co Ltd	-	32,240	
Listed on the Stock Exchange of Taiwan			
MediaTek Inc	-	1,000	
Silergy Corp	2,000	1,000	

FSSA China All Cap Fund Details in Respect of Financial Derivative Instruments (Unaudited) As at 31 December 2024

The financial derivative instruments held by the fund as at 31st December 2024 are summarized below:

Spot foreign exchange contracts

The details of spot foreign exchange contracts held by the fund as at 31st December 2024 are as follows:

As at 31st December 2024 Nil

FSSA China All Cap Fund Statement of Net Assets (Unaudited) As at 31 December 2024

_

	(Unaudited) 31 December 2024 US\$	(Audited) 30 June 2024 US\$
Assets		
Investments	7,184,049	6,669,010
Interest receivable	5	8
Dividend receivable	-	26,141
Amounts receivable on management fee rebate	61,286	62,983
Cash and cash equivalents	131,123	97,257
Total assets	7,376,463	6,855,399
T • 1 • • • •		
Liabilities	52 120	52 122
Amounts payable on redemption	53,132	53,132
Accounts payable and accrued expenses	151,796	153,672
Total liabilities (excluding net assets attributable to unitholders)	204,928	206,804
Net assets attributable to unitholders	7,171,535	6,648,595
Number of units in issue	100 007 70	104 (55 21
- Class I (USD)	100,997.72	104,655.21
- Class II (USD)	29,712.32 267,959.27	30,141.43
- Class III (USD)		267,959.27
Net assets attributable to unitholders per unit		
- Class I (USD)	7.94	7.28
- Class II (USD)	108.19	99.19
- Class III (USD)	11.82	10.80

Note: Semi-annual report of the sub-fund has been prepared in accordance with the same accounting policies adopted in the 2024 annual financial statements.

FSSA China All Cap Fund Statement of Comprehensive Income (Unaudited) For the period ended 31 December 2024

	(Unaudited) For the period from 1st July 2024 to 31st December 2024 US\$	(Unaudited) For the period from 1st July 2023 to 31st December 2023 US\$
Income		
Interest on bank deposits	949	844
Dividend on investments Net gains/(losses) on investments and derivative financial	78,768	61,195
instruments	589,549	(888,286)
Management fee rebate	39,154	44,061
Other income	1,362	- 140
Exchange (losses)/gains	(842)	149
Total net profit/(loss)	708,940	(782,037)
Expenses		
Management fee Note 2	58,070	47,298
Trustee's fee Note 1	3,809	3,832
Administration fee Note 1	6,000	6,019
Auditor's remuneration	24,016	31,850
Legal and professional fees	4,930	1,432
Transaction costs Note 2	3,321	2,701
Safe custody and bank charges Note 1	172	64
Interest expenses Other operating expenses ^{Note 1}	1 9,283	2 10,283
	·	
Total operating expenses	109,602	103,481
Profit/(loss) before tax	599,338	(885,518)
Withholding tax	(4,764)	(3,541)
Increase/(decrease) in net assets attributable to unitholders from operations	594,574	(889,059)

Note 1 During the period ended 31 December 2024 and 2023, other than trustee's fee, administration fee and safe custody and bank charges paid to the Trustee or its Connected Persons, other respective amounts paid to the Trustee or its Connected Persons were as follows:

	(Unaudited) For the period from 1st July 2024 to 31st December 2024 US\$	(Unaudited) For the period from 1st July 2023 to 31st December 2023 US\$
Other operating expenses	8,514	9,699

Note ² During the period ended 31 December 2024 and 2023, other than Management fee paid to the Manager, other respective amounts paid to the Manager or its Connected Persons were as follows:

	(Unaudited) For the period from 1st July 2024 to 31st December 2024 US\$	(Unaudited) For the period from 1st July 2023 to 31st December 2023 US\$
Transaction costs	13	-

FSSA China All Cap Fund Statement of Changes in Net Assets Attributable to Unitholders (Unaudited) For the period ended 31 December 2024

	(Unaudited) For the period from 1st July 2024 to 31st December 2024 US\$	(Unaudited) For the period from 1st July 2023 to 31st December 2023 US\$
Net assets attributable to unitholders at 1 July	6,648,595	7,831,953
Allotment of units	4,022	1,218
Redemption of units	(75,656)	(146,898)
Increase/(decrease) in net assets attributable to unitholders from operations	594,574	(889,059)
Net assets attributable to unitholders at 31 December	7,171,535	6,797,214
	(Unaudited) For the period from 1st July 2024 to 31st December 2024 Units	(Unaudited) For the period from 1st July 2023 to 31st December 2023 Units
Class I (USD)		
Balance at the beginning of the period Allotment of units Redemption of units	104,655.21 426.98 (4,084.47)	114,464.75 158.19 (9,816.11)
Balance at the end of the period	100,997.72	104,806.83
Class II (USD)		
Balance at the beginning of the period Allotment of units	30,141.43	31,294.15
Redemption of units	(429.11)	(647.90)
Balance at the end of the period	29,712.32	30,646.25
Class III (USD)		
Balance at the beginning of the period Allotment of units	267,959.27	267,959.27
Redemption of units	-	-

Cash flows from operating activitiesPayments on purchase of investments and derivative financial instruments(1,124,067)(849,784)Proceeds from sale of investments and derivative financial instruments1,198,577963,893Interest received952839Dividend received100,14584,831Other income received1,362Management fee rebate received40,85120,906Management fee paid(49,381)(26,784)Turstee's fee paid(3,713)(4,007)Administration fee paid(6,000)(6,000)Auditor's remuneration paid(38,778)(37,986)Transaction costs paid(10,284)(13,677)Other operating expenses paid(10,284)(13,677)Net cash generated from operating activities106,342129,528Allotment of units4,0221,218Redemption of units(71,634)(145,680)Net cash used in financing activities(71,634)(145,680)Iterest cash used in financing activities34,708(16,152)Effect of foreign exchange rate changes(842)149Cash and cash equivalents at the beginning of the period97,257136,804Cash and cash equivalents at the end of the period131,123120,801Analysis of balance of cash and cash equivalents121,122120,801		(Unaudited) For the period from 1st July 2024 to 31st December 2024 US\$	(Unaudited) For the period from 1st July 2023 to 31st December 2023 US\$
financial instruments(1,124,067)(849,784)Proceeds from sale of investments and derivative financial instruments1,198,577963,893Interest received952839Dividend received100,14584,831Other income received1,362-Management fee rebate received40,85120,906Management fee rebate received(3,713)(4,007)Administration fee paid(3,713)(4,007)Administration fee paid(3,8778)(37,986)Transaction costs paid(3,321)(2,701)Interest paid(1)(2)Other operating expenses paid(10,284)(13,677)Net cash generated from operating activities106,342129,528Allotment of units4,0221,218Redemption of units(71,634)(146,898)Net cash used in financing activities34,708(16,152)Effect of foreign exchange rate changes(842)149Cash and cash equivalents at the beginning of the period97,257136,804Cash and cash equivalents at the end of the period131,123120,801Analysis of balance of cash and cash equivalents131,123120,801	Cash flows from operating activities		
Proceeds from sale of investments and derivative financial instruments1,198,577963,893Interest received952839Dividend received100,14584,831Other income received1,362-Management fee rebate received40,85120,906Management fee paid(49,381)(26,784)Trustee's fee paid(3,713)(4,007)Administration fee paid(6,000)(6,000)Additor's remuneration paid(38,778)(37,986)Transaction costs paid(1)(2)Other operating expenses paid(10,284)(13,677)Net cash generated from operating activities106,342129,528Allotment of units4,0221,218Redemption of units(75,656)(146,898)Net cash used in financing activities(71,634)(145,680)Net increase/(decrease) in cash and cash equivalents34,708(16,152)Effect of foreign exchange rate changes(842)149Cash and cash equivalents at the end of the period97,257136,804Analysis of balance of cash and cash equivalents131,123120,801			
financial instruments1,198,577963,893Interest received952839Dividend received100,14584,831Other income received1,362-Management fee rebate received40,85120,906Management fee paid(49,381)(26,784)Trustee's fee paid(3,713)(4,007)Administration fee paid(6,000)(6,000)Auditor's remuneration paid(38,778)(37,986)Transaction costs paid(3,321)(2,701)Interest paid(10,284)(13,677)Net cash generated from operating activities106,342129,528Allotment of units4,0221,218Redemption of units(75,656)(146,898)Net cash used in financing activities(71,634)(145,680)Net increase/(decrease) in cash and cash equivalents34,708(16,152)Effect of foreign exchange rate changes(842)149Cash and cash equivalents at the beginning of the period97,257136,804Cash and cash equivalents at the end of the period131,123120,801Analysis of balance of cash and cash equivalents131,123120,801		(1,124,067)	(849,784)
Interest received952839Dividend received100,14584,831Other income received1,362-Management fee rebate received40,85120,906Management fee paid(49,381)(26,784)Trustee's fee paid(3,713)(4,007)Administration fee paid(6,000)(6,000)Auditor's remuneration paid(38,778)(37,986)Transaction costs paid(33,21)(2,701)Interest paid(1)(2)Other operating expenses paid(10,284)(13,677)Net cash generated from operating activities106,342129,528Allotment of units4,0221,218Redemption of units(71,634)(145,680)Net cash used in financing activities34,708(16,152)Effect of foreign exchange rate changes(842)149Cash and cash equivalents at the beginning of the period97,257136,804Cash and cash equivalents at the end of the period131,123120,801Analysis of balance of cash and cash equivalents131,123120,801		1 100 555	
Dividend received100,14584,831Other income received1,362-Management fee robate received40,85120,906Management fee paid(49,381)(26,784)Trustee's fee paid(3,713)(4,007)Administration fee paid(6,000)(6,000)Auditor's remuneration paid(38,778)(37,986)Transaction costs paid(3,321)(2,701)Interest paid(10,284)(13,677)Other operating expenses paid(10,284)(13,677)Net cash generated from operating activities106,342129,528Cash flows from financing activities(75,656)(146,898)Net cash used in financing activities(71,634)(145,680)Net increase/(decrease) in cash and cash equivalents34,708(16,152)Effect of foreign exchange rate changes(842)149Cash and cash equivalents at the beginning of the period97,257136,804Cash and cash equivalents at the end of the period131,123120,801Analysis of balance of cash and cash equivalents131,123120,801			
Other income received1,362Management fee rebate received40,851Management fee rebate received40,851Management fee paid(49,381)Trustee's fee paid(3,713)Administration fee paid(6,000)Auditor's remuneration paid(38,778)Transaction costs paid(3,321)Interest paid(1)(2)(1)Other operating expenses paid(10,284)(13,677)(13,677)Net cash generated from operating activities106,342Allotment of units4,022Redemption of units(75,656)Net cash used in financing activities(71,634)Net cash used in financing activities34,708Net increase/(decrease) in cash and cash equivalents34,708Cash and cash equivalents at the beginning of the period97,257Analysis of balance of cash and cash equivalents131,123Analysis of balance of cash and cash equivalents131,123			
Management fee rebate received40,85120,906Management fee paid(49,381)(26,784)Trustee's fee paid(3,713)(4,007)Administration fee paid(6,000)(6,000)Auditor's remuneration paid(38,778)(37,986)Transaction costs paid(1)(2)Interest paid(1)(2)Other operating expenses paid(10,284)(13,677)Net cash generated from operating activities106,342129,528Cash flows from financing activities(75,656)(146,898)Net cash used in financing activities(71,634)(145,680)Net increase/(decrease) in cash and cash equivalents34,708(16,152)Effect of foreign exchange rate changes(842)149Cash and cash equivalents at the beginning of the period97,257136,804Cash and cash equivalents at the end of the period131,123120,801Analysis of balance of cash and cash equivalents131,123120,801			84,831
Management fee paid(49,381)(26,784)Trustee's fee paid(3,713)(4,007)Administration fee paid(6,000)(6,000)Auditor's remuneration paid(38,778)(37,986)Transaction costs paid(1)(2,701)Interest paid(1)(2)Other operating expenses paid(10,284)(13,677)Net cash generated from operating activities106,342129,528Cash flows from financing activities		-	- 20.906
Trustee's fee paid(3,713)(4,007)Administration fee paid(6,000)(6,000)Auditor's remuneration paid(38,778)(37,986)Transaction costs paid(3,321)(2,701)Interest paid(1)(2)Other operating expenses paid(10,284)(13,677)Net cash generated from operating activities106,342129,528Cash flows from financing activities106,342129,528Allotment of units4,0221,218Redemption of units(75,656)(146,898)Net cash used in financing activities(71,634)(145,680)Interease/(decrease) in cash and cash equivalents34,708(16,152)Effect of foreign exchange rate changes(842)149Cash and cash equivalents at the beginning of the period97,257136,804Cash and cash equivalents at the end of the period131,123120,801Analysis of balance of cash and cash equivalents131,123120,801	-	-	
Administration fee paid(6,000)(6,000)Auditor's remuneration paid(38,778)(37,986)Transaction costs paid(3,321)(2,701)Interest paid(1)(2)Other operating expenses paid(10,284)(13,677)Net cash generated from operating activities106,342129,528Cash flows from financing activities106,342129,528Allotment of units4,0221,218Redemption of units(75,656)(146,898)Net cash used in financing activities(71,634)(145,680)Net increase/(decrease) in cash and cash equivalents34,708(16,152)Effect of foreign exchange rate changes(842)149Cash and cash equivalents at the beginning of the period97,257136,804Cash and cash equivalents at the end of the period131,123120,801Analysis of balance of cash and cash equivalents131,123120,801	• •		
Auditor's remuneration paid(38,778)(37,986)Transaction costs paid(3,321)(2,701)Interest paid(1)(2)Other operating expenses paid(10,284)(13,677)Net cash generated from operating activities106,342129,528Cash flows from financing activities106,342129,528Allotment of units4,0221,218Redemption of units(75,656)(146,898)Net cash used in financing activities(71,634)(145,680)Net cash used in financing activities34,708(16,152)Effect of foreign exchange rate changes(842)149Cash and cash equivalents at the beginning of the period97,257136,804Cash and cash equivalents at the end of the period131,123120,801Analysis of balance of cash and cash equivalents131,123120,801			
Transaction costs paid(3,321)(2,701)Interest paid(1)(2)Other operating expenses paid(10,284)(13,677)Net cash generated from operating activities106,342129,528Cash flows from financing activities106,342129,528Allotment of units4,0221,218Redemption of units(75,656)(146,898)Net cash used in financing activities(71,634)(145,680)Net increase/(decrease) in cash and cash equivalents34,708(16,152)Effect of foreign exchange rate changes(842)149Cash and cash equivalents at the beginning of the period97,257136,804Cash and cash equivalents at the end of the period131,123120,801Analysis of balance of cash and cash equivalents131,123120,801			
Interest paid(1)(2)Other operating expenses paid(10,284)(13,677)Net cash generated from operating activities106,342129,528Cash flows from financing activities4,0221,218Allotment of units4,0221,218Redemption of units(75,656)(146,898)Net cash used in financing activities(71,634)(145,680)Net increase/(decrease) in cash and cash equivalents34,708(16,152)Effect of foreign exchange rate changes(842)149Cash and cash equivalents at the beginning of the period97,257136,804Cash and cash equivalents at the end of the period131,123120,801Analysis of balance of cash and cash equivalents131,123120,801	-		
Net cash generated from operating activities106,342129,528Cash flows from financing activities4,0221,218Allotment of units4,0221,218Redemption of units(75,656)(146,898)Net cash used in financing activities(71,634)(145,680)Net increase/(decrease) in cash and cash equivalents34,708(16,152)Effect of foreign exchange rate changes Cash and cash equivalents at the beginning of the period97,257136,804Cash and cash equivalents at the end of the period131,123120,801Analysis of balance of cash and cash equivalents131,123120,801		(1)	
Cash flows from financing activitiesAllotment of units4,0221,218Redemption of units(75,656)(146,898)Net cash used in financing activities(71,634)(145,680)Net increase/(decrease) in cash and cash equivalents34,708(16,152)Effect of foreign exchange rate changes(842)149Cash and cash equivalents at the beginning of the period97,257136,804Cash and cash equivalents at the end of the period131,123120,801Analysis of balance of cash and cash equivalents131,123120,801		(10,284)	
Allotment of units4,0221,218Redemption of units(75,656)(146,898)Net cash used in financing activities(71,634)(145,680)Net increase/(decrease) in cash and cash equivalents34,708(16,152)Effect of foreign exchange rate changes(842)149Cash and cash equivalents at the beginning of the period97,257136,804Cash and cash equivalents at the end of the period131,123120,801Analysis of balance of cash and cash equivalents131,123120,801	Net cash generated from operating activities	106,342	129,528
Redemption of units(75,656)(146,898)Net cash used in financing activities(71,634)(145,680)Net increase/(decrease) in cash and cash equivalents34,708(16,152)Effect of foreign exchange rate changes Cash and cash equivalents at the beginning of the period97,257136,804Cash and cash equivalents at the end of the period131,123120,801Analysis of balance of cash and cash equivalents131,123120,801	Cash flows from financing activities		
Net cash used in financing activities(71,634)(145,680)Net increase/(decrease) in cash and cash equivalents34,708(16,152)Effect of foreign exchange rate changes Cash and cash equivalents at the beginning of the period(842)149Cash and cash equivalents at the end of the period97,257136,804Cash and cash equivalents at the end of the period131,123120,801Analysis of balance of cash and cash equivalents131,123120,801	Allotment of units	4,022	1,218
Net increase/(decrease) in cash and cash equivalents34,708(16,152)Effect of foreign exchange rate changes Cash and cash equivalents at the beginning of the period(842)149Cash and cash equivalents at the end of the period97,257136,804Cash and cash equivalents at the end of the period131,123120,801Analysis of balance of cash and cash equivalents131,123120,801	Redemption of units	(75,656)	(146,898)
Effect of foreign exchange rate changes(842)149Cash and cash equivalents at the beginning of the period97,257136,804Cash and cash equivalents at the end of the period131,123120,801Analysis of balance of cash and cash equivalents131,123120,801	Net cash used in financing activities	(71,634)	(145,680)
Cash and cash equivalents at the beginning of the period97,257136,804Cash and cash equivalents at the end of the period131,123120,801Analysis of balance of cash and cash equivalents131,123120,801	Net increase/(decrease) in cash and cash equivalents	34,708	(16,152)
Cash and cash equivalents at the beginning of the period97,257136,804Cash and cash equivalents at the end of the period131,123120,801Analysis of balance of cash and cash equivalents131,123120,801	Effect of foreign exchange rate changes	(842)	149
Analysis of balance of cash and cash equivalents			
	Cash and cash equivalents at the end of the period	131,123	120,801
Cook at hardra 121,122 120,801	Analysis of balance of cash and cash equivalents		
Cash at banks 151,125 120,801	Cash at banks	131,123	120,801

Manager	First Sentier Investors (Hong Kong) Limited 25th Floor, One Exchange Square 8 Connaught Place Central Hong Kong
Directors of the Manager	Chung Piau Chia Lauren Prendiville Emma Kathryn Tetley (Appointed on 26 July 2024) Christy Chin Ting Goh (Appointed on 26 July 2024) Michael David Stapleton (Resigned on 23 July 2024) Lucinda Kate Dowling (Resigned on 23 July 2024)
Trustee and Registrar	HSBC Institutional Trust Services (Asia) Limited 1 Queen's Road Central Hong Kong
Auditor	Deloitte Touche Tohmatsu 35/F, One Pacific Place 88 Queensway Hong Kong
Legal Advisor to the Manager	Deacons 5th Floor Alexandra House 18 Charter Road Central Hong Kong

This page is intentionally left blank

